Peregrine Capital Management LLC Invests $5.71 Million in NewAmsterdam Pharma Company N.V. $NAMS

Peregrine Capital Management LLC purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 178,493 shares of the company’s stock, valued at approximately $5,714,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of NAMS. Capital World Investors raised its holdings in shares of NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Duquesne Family Office LLC increased its position in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after acquiring an additional 1,091,525 shares during the period. Castle Hook Partners LP purchased a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $38,062,000. Adage Capital Partners GP L.L.C. lifted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after purchasing an additional 845,110 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.74% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS opened at $35.17 on Thursday. NewAmsterdam Pharma Company N.V. has a 12 month low of $18.08 and a 12 month high of $42.21. The company has a 50-day moving average of $32.82 and a 200-day moving average of $33.10. The company has a market cap of $4.11 billion, a P/E ratio of -19.65 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Analyst Upgrades and Downgrades

NAMS has been the subject of several recent research reports. Truist Financial started coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and an average price target of $49.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.